ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1

Historical Holders from Q4 2021 to Q3 2025

Type / Class
Debt / NOTE 4.000%11/1
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal, excl. options
28,696,440
Holdings value
$40,994,280
% of all portfolios
0%
Number of holders
9
Number of buys
4
Number of sells
-2
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of ESPERION THERAPEUTICS INC NE - NOTE 4.000%11/1

Period Principal Value Change Price Investors
2025 Q3 28,696,440 $40,994,280 +$186,254 $0.998 9
2025 Q2 21,445,940 $40,691,968 +$258,902 $0.9857 11
2025 Q1 17,805,940 $37,176,006 +$4,762,266 $0.983 9
2024 Q4 33,246,000 $32,179,247 -$171,476,277 $0.9697 6
2024 Q3 206,228,879 $255,900,035 -$4,680,942 $0.9487 16
2024 Q2 152,469,254 $187,829,878 +$194,776 $0.9231 18
2024 Q1 168,363,404 $171,853,927 -$14,901,542,141 $0.8301 17
2023 Q4 210,454,000 $122,864,861 +$10,846,961 $0.5834 18
2023 Q3 192,120,851 $110,572,628 -$4,399,266 $0.52 17
2023 Q2 198,299,351 $109,095,639 -$6,106,943 $0.4971 18
2023 Q1 236,594,851 $103,500,121 -$397,411 $0.4006 20
2022 Q4 235,496,164 $132,860,346 +$4,389,560 $0.5496 20
2022 Q3 214,894,764 $128,456,175 -$42,773 $0.5578 19
2022 Q2 214,994,764 $125,766,000 +$772,275 $0.5443 19
2022 Q1 212,146,264 $118,647,578 +$5,205,374 $0.5157 20
2021 Q4 199,553,764 $115,520,638 +$115,520,638 $0.5275 17